Last reviewed · How we verify
Disease caused by Severe acute respiratory syndrome coronavirus 2 — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Veklury | remdesivir | Gilead Sciences | Nucleotide analog RNA polymerase inhibitor | SARS-CoV-2 RNA polymerase | 2020-01-01 | |
| Veklury | Veklury | ANRS, Emerging Infectious Diseases | Nucleoside analog prodrug | NS5, Replicase polyprotein 1ab | ||
| Xocova | ENSITRELVIR | Shionogi & Co., Ltd. |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- ANRS, Emerging Infectious Diseases · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2
- Gilead Sciences · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2
- Shionogi & Co., Ltd. · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Disease caused by Severe acute respiratory syndrome coronavirus 2:
- Disease caused by Severe acute respiratory syndrome coronavirus 2 treatment updates — RSS
- Disease caused by Severe acute respiratory syndrome coronavirus 2 treatment updates — Atom
- Disease caused by Severe acute respiratory syndrome coronavirus 2 treatment updates — JSON
Cite this brief
Drug Landscape (2026). Disease caused by Severe acute respiratory syndrome coronavirus 2 — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disease-caused-by-severe-acute-respiratory-syndrome-coronavirus-2. Accessed 2026-06-10.
Related
- Disease caused by Severe acute respiratory syndrome coronavirus 2 full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing